Full-Time

Senior Specialty Sales Professional

Updated on 7/22/2026

Mallinckrodt

Mallinckrodt

1,001-5,000 employees

Specialty pharmaceutical developer, manufacturer, distributor

Compensation Overview

$121k - $174k/yr

+ Bonus

Brooklyn, NY, USA

Remote

Remote within the United States; up to 30% travel may be required.

Category
Sales & Account Management (1)

Get referred to Mallinckrodt

Find people who can refer or advise you

Requirements
  • Bachelor’s degree with 3-5 years’ relevant experience preferred.
  • Biopharmaceutical Industry experience required.
  • B2B sales experience required.
  • All newly-hired experiences (i.e. not entry level) Sales Professionals should enter at this level, regardless of their tenure or experience elsewhere.
  • Able to understand technical issues (medical, computer, data analysis)
  • Overnight travel is necessary (30% or more). Territory specific.
  • Must have valid driver’s license.
  • Ability to safely operate a motor vehicle.
  • Ability to lift up to 10 pounds.
Responsibilities
  • Establish and maintain call objectives for geography with minimal consultation with Area Sales Manager to assure proper portfolio balance and planned actions.
  • Develop and complete appropriate territory business plan for optimal activity.
  • Create effective call plans that include who to contact, how frequently to contact them, and what products to focus on for each call.
  • Develop and execute an individual prescriber plan of action for maximum selling opportunity as developed through territory business plan.
  • Understand and use approved promotional materials to support marketing message.
  • Employ effective selling model and techniques aligning to current strategies set forth by Keenova.
  • Attain and maintain performance guidelines for the following metrics: call activity, appropriate utilization of samples, Quarterly Business Plan update.
  • Incorporate and execute on all expectations regarding adherence to all FDA, PDMA, HPPA, and Keenova established Policies on all interactions with Healthcare Professionals.
  • Maintain up-to-date database to document sales call information, trends, future call objectives, sampling data and overall territory performance.
  • Effectively manage sample accountability program.
  • Execute all administrative responsibilities including but not limited to: Complete weekly activity reports as needed.
  • Synchronize, check email, and voicemail at least once a day.
  • Update ASM on territory business plan on a quarterly basis.
  • Complete and track expense reports every 2 weeks at minimum or at the discretion of the ASM.
  • Maintain an in-depth and sophisticated knowledge of specific healthcare issues, products and diseases states that enables quality engagement in meaningful dialogue, builds credibility and add value when calling on health care professionals.
  • Maintain an expert product knowledge base including patient education, consumer education, and factors influencing the market environment.
  • Learn and execute core sales training curriculum.
  • Learn and apply information regarding new and existing products as demonstrated by tests and Field Contact Reports.
  • Gain understanding of local ‘Payer’ environment and incorporate appropriate sales strategies.
  • Prepare for, attend, and actively participate in all required sales conferences and training classes at local and/or remote locations.

Mallinckrodt is a global specialty pharmaceutical company that develops, manufactures, and distributes drugs and therapies for complex and rare conditions, serving healthcare providers, hospitals, and patients mainly in the United States and Europe. Its products target areas such as autoimmune diseases, rare diseases, and critical care, and the business rests on research and development, manufacturing, and sales. The company differentiates itself through a patient-centric approach, a commitment to integrity, ongoing innovation, and collaboration, grounded in more than 150 years of experience and a focus on ESG initiatives. Its goal is to improve the health and well-being of patients worldwide by delivering specialty medicines and advancing sustainable practices.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Hazelwood, Missouri

Founded

1867

Get referred to Mallinckrodt

Find people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Merger with Endo completed, forming NYSE-listed therapeutics leader by Q4 2025.
  • Reduced debt 47% to $865.6M and grew Acthar Gel sales 14.2% in 2024.
  • Sold Therakos for $925M, optimizing portfolio for specialty pharmaceuticals.

What critics are saying

  • Endo merger integration disrupts operations, overloading with $6.7B debt.
  • Therakos sale drops immunotherapy revenue, losing edge to Amgen immediately.
  • Acthar Gel's $300K pricing triggers DOJ probe and $500M fines within 18 months.

What makes Mallinckrodt unique

  • Mallinckrodt specializes in Acthar Gel for autoimmune diseases over 150 years.
  • Focuses on rare diseases and critical care therapies for underserved patients.
  • Launched Acthar Gel self-injectable to improve patient adherence and convenience.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Performance Bonus

Relocation Assistance

Growth & Insights and Company News

Headcount

6 month growth

-5%

1 year growth

-5%

2 year growth

-5%
PR Newswire
Nov 10th, 2025
Par Health Completes Spin-Off from Mallinckrodt, Creating an Independent Leader in Generic Pharmaceuticals and Sterile Injectables

Launches as Top 15 U.S. Generic Drug Manufacturer, Largest U.S. Producer of Active Pharmaceutical Ingredients and Premier U.S. Producer of Sterile Injectables...

Contract Pharma
Aug 6th, 2025
Mallinckrodt Names Christiana Stamoulis President and CFO

Mallinckrodt plc appointed Christiana Stamoulis as President and Chief Financial Officer, effective September 22, 2025.

Stock Titan
Aug 1st, 2025
Mallinckrodt-Endo Merger Creates Therapeutics Leader

Mallinckrodt and Endo have completed a merger to form a global therapeutics leader. The companies will combine their generics businesses and Endo's sterile injectables business, which will be spun off as an independent company by Q4 2025. The newly branded company will be listed on the New York Stock Exchange following the spin-off.

The Business Journals
Jul 25th, 2025
Mallinckrodt Reaches $7B Merger Milestone

Mallinckrodt has reached a milestone in a $7 billion merger deal.

Sharecast
Mar 13th, 2025
Mallinckrodt and Endo to merge in $6.7bn deal

Pharmaceutical firm Mallinckrodt said on Thursday that it has agreed to merge with Endo in a $6.7bn deal.